Tenaya Therapeutics (NASDAQ:TNYA) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Tenaya Therapeutics (NASDAQ:TNYA) from a hold rating to a sell rating in a report published on Saturday.

Several other research firms have also recently weighed in on TNYA. Leerink Partners reaffirmed an “outperform” rating and set a $2.00 price objective on shares of Tenaya Therapeutics in a research report on Thursday. Morgan Stanley set a $2.00 target price on Tenaya Therapeutics in a research report on Thursday, January 8th. Lifesci Capital upgraded Tenaya Therapeutics to a “strong-buy” rating in a research note on Thursday, March 5th. Chardan Capital restated a “buy” rating and set a $8.00 price target on shares of Tenaya Therapeutics in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenaya Therapeutics in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $4.00.

Tenaya Therapeutics Trading Down 4.5%

Shares of NASDAQ TNYA opened at $0.85 on Friday. The firm has a fifty day simple moving average of $0.73 and a two-hundred day simple moving average of $1.12. Tenaya Therapeutics has a 12 month low of $0.36 and a 12 month high of $2.35. The firm has a market capitalization of $139.57 million, a PE ratio of -1.37 and a beta of 3.22.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its earnings results on Wednesday, March 11th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). On average, sell-side analysts predict that Tenaya Therapeutics will post -1.35 earnings per share for the current year.

Insiders Place Their Bets

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III sold 3,511,826 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $0.56, for a total transaction of $1,966,622.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 8,594,047 shares of company stock valued at $5,430,207 in the last 90 days. 48.65% of the stock is currently owned by corporate insiders.

Institutional Trading of Tenaya Therapeutics

A number of hedge funds have recently made changes to their positions in TNYA. Scientech Research LLC bought a new position in Tenaya Therapeutics during the 3rd quarter valued at approximately $27,000. Mirador Capital Partners LP boosted its holdings in Tenaya Therapeutics by 38.2% in the third quarter. Mirador Capital Partners LP now owns 23,500 shares of the company’s stock worth $38,000 after acquiring an additional 6,500 shares in the last quarter. Comerica Bank bought a new stake in Tenaya Therapeutics in the first quarter worth $50,000. Savant Capital LLC bought a new stake in Tenaya Therapeutics in the second quarter worth $52,000. Finally, Cerity Partners LLC grew its stake in shares of Tenaya Therapeutics by 403.5% in the second quarter. Cerity Partners LLC now owns 110,336 shares of the company’s stock worth $67,000 after acquiring an additional 88,424 shares during the last quarter. 90.54% of the stock is owned by institutional investors.

Tenaya Therapeutics News Summary

Here are the key news stories impacting Tenaya Therapeutics this week:

• Positive Sentiment: Positive TN‑301 DMD data and a collaboration with Alnylam triggered a sharp rally earlier this week, boosting optimism about Tenaya’s Duchenne muscular dystrophy program and potential commercial/strategic value. Article Title
• Positive Sentiment: Lifesci Capital published a set of EPS forecasts and reiterated a “Strong‑Buy” stance, modeling smaller losses for FY2026 (‑$0.59) than the street consensus (‑$1.35) and forecasting Q1–Q4 2026 EPS of about (‑$0.14) each — a view that supports upside if pipeline progress continues. Article Title
• Negative Sentiment: Wall Street Zen downgraded TNYA to a “Sell,” which likely pressured the stock after the earlier gains by introducing near‑term pessimism and prompting profit‑taking from short‑term holders. Article Title

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.